Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) reported that it has received Institutional Review Board approval to proceed with its clinical trial to treat Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. FDA had previously cleared the Company’s...
Moderna, Inc. (NASDAQ: MRNA) has announced positive data from its ConquerRSV Phase 3 trial of mRNA-1345, an investigational mRNA vaccine that targets respiratory syncytial virus in older adults. Following review by an independent Data and Safety Monitoring Board...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is taking a sharp hit in premarket trading Thursday, with shares falling as much as 25% after the company delivered an underwhelming clinical trial update late Wednesday. The news centered around its late-stage trial of...
Shares of MP Materials (NYSE: MP) surged more than 50% on Thursday after the company announced that the U.S. Department of Defense (DoD) will invest $400 million in the rare earth miner, becoming its largest shareholder in the process. The deal marks a significant...
Shares of ProKidney Corp (NASDAQ: PROK) soared more than 25% in Thursday afternoon trading after the company reported encouraging topline results from its Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease (CKD) and diabetes. The...